Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023
BOTHELL, Wash.–(BUSINESS WIRE)–
Seagen Inc. (Nasdaq: SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023.
Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call.
About Seagen
Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together with urgency to improve and extend the lives of people living with cancer. An ADC technology trailblazer, approximately one-third of FDA-approved and marketed ADCs use Seagen technology. Seagen is headquartered in Bothell, Washington and has locations in California, Canada, Switzerland and across Europe. For additional information, visit www.seagen.com and follow us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231012765576/en/
For Investors
Douglas Maffei, Ph.D.
Vice President, Investor Relations
(425) 527-4881
[email protected]
For Media
David Caouette
Vice President, Corporate Communications
(310) 430-3476
[email protected]
KEYWORDS: United States North America Washington
INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology
MEDIA:
| Logo |
 |